JP2014520892A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520892A5
JP2014520892A5 JP2014521786A JP2014521786A JP2014520892A5 JP 2014520892 A5 JP2014520892 A5 JP 2014520892A5 JP 2014521786 A JP2014521786 A JP 2014521786A JP 2014521786 A JP2014521786 A JP 2014521786A JP 2014520892 A5 JP2014520892 A5 JP 2014520892A5
Authority
JP
Japan
Prior art keywords
botulinum
composition according
botulinum toxin
type
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/047405 external-priority patent/WO2013013042A1/en
Publication of JP2014520892A publication Critical patent/JP2014520892A/ja
Publication of JP2014520892A5 publication Critical patent/JP2014520892A5/ja
Pending legal-status Critical Current

Links

JP2014521786A 2011-07-20 2012-07-19 脂肪沈着物を処置するための方法におけるボツリヌス毒素の使用 Pending JP2014520892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509700P 2011-07-20 2011-07-20
US61/509,700 2011-07-20
PCT/US2012/047405 WO2013013042A1 (en) 2011-07-20 2012-07-19 Botulinum toxins for use in a method for treatment of adipose deposits

Publications (2)

Publication Number Publication Date
JP2014520892A JP2014520892A (ja) 2014-08-25
JP2014520892A5 true JP2014520892A5 (cg-RX-API-DMAC7.html) 2016-06-16

Family

ID=46601917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521786A Pending JP2014520892A (ja) 2011-07-20 2012-07-19 脂肪沈着物を処置するための方法におけるボツリヌス毒素の使用

Country Status (12)

Country Link
US (1) US20140127188A1 (cg-RX-API-DMAC7.html)
EP (1) EP2734224A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014520892A (cg-RX-API-DMAC7.html)
KR (1) KR20140082956A (cg-RX-API-DMAC7.html)
CN (1) CN103702681A (cg-RX-API-DMAC7.html)
AU (1) AU2012283968B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014001066A2 (cg-RX-API-DMAC7.html)
CA (1) CA2841955A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN00254A (cg-RX-API-DMAC7.html)
MX (1) MX2014000612A (cg-RX-API-DMAC7.html)
RU (1) RU2014103543A (cg-RX-API-DMAC7.html)
WO (1) WO2013013042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9655926B1 (en) 2013-08-23 2017-05-23 Amiya Prasad Treatment for hair thinning and hair loss
WO2016021985A1 (ko) * 2014-08-07 2016-02-11 김상덕 보툴리눔 독소와 공기의 혼합물을 포함하는 안면 윤곽 교정용 조성물 및 이를 이용한 안면 윤곽 교정 방법
US11111256B2 (en) 2015-12-18 2021-09-07 Jiangsu Nata Opto-Electronic Materials Co. Ltd. High purity trisilylamine, methods of making, and use
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
RU2019141383A (ru) * 2017-05-18 2021-06-18 Реванс Терапьютикс, Инк. (Revance Therapeutics, Inc.) Способы лечения цервикальной дистонии
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
CA2505930C (en) 1997-07-15 2008-01-29 Richard A. Schmidt Use of botulinum toxin in the preparation of a pharmaceutical composition for treating urinary retention
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
EP1545207B1 (en) * 2002-08-19 2018-03-14 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US8404249B2 (en) * 2004-03-03 2013-03-26 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
CN103919690B (zh) * 2005-12-01 2020-07-31 麻萨诸塞州洛厄尔大学 肉毒杆菌纳米乳液
WO2009026949A1 (en) * 2007-08-31 2009-03-05 Dsm Ip Assets B.V. 4-amidino benzylamines for cosmetic and/or dermatological use
US20090297632A1 (en) * 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
CA2726836C (en) * 2008-06-26 2019-06-18 Anterios, Inc. Use of nanoemulsions in the manufacture of a medicament for treating skin disorders
WO2010099587A1 (en) * 2009-03-02 2010-09-10 Doris Hexsel Medicinal cosmetic lipoatrophy

Similar Documents

Publication Publication Date Title
JP2014520892A5 (cg-RX-API-DMAC7.html)
JP2014505733A5 (cg-RX-API-DMAC7.html)
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
JP2010222367A5 (cg-RX-API-DMAC7.html)
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
IN2014MN02288A (cg-RX-API-DMAC7.html)
IN2014DN09434A (cg-RX-API-DMAC7.html)
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
MX340985B (es) Compuestos de n-heteroarilo.
EA201391119A1 (ru) Системы доставки наночастиц, их получение и применение
PH12017500706B1 (en) Composition containing extract or fraction of genus justicia plant
WO2015195684A3 (en) Small molecule anti-scarring agents
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX384947B (es) Composiciones en suspension de ciclosporina a para inyecciones subconjuntivales y perioculares.
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
JP2015508052A5 (cg-RX-API-DMAC7.html)
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
EA201690574A1 (ru) Применение пидотимода в лечении заболеваний, связанных с воспалением
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну